A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Bibliometric and Visual Analysis of Alzheimer's Disease and Herpes Simplex Virus Type 1 Infection Between 1990 and 2024.Journal of multidisciplinary healthcare · 2025
   Article
2. Human Antibodies against Herpes Simplex Virus 2 Glycoprotein G Do Not Neutralize but Mediate Antibody-Dependent Cellular Cytotoxicity.Antibodies (Basel, Switzerland) · 2024
   Article
3. Herpes Simplex Virus Type 2 Is More Difficult to Neutralize by Antibodies Than Herpes Simplex Virus Type 1.Vaccines · 2020
   Article
4. A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits.Vaccines · 2020
   Article
5. The Roles of Host and Viral Antibody Fc Receptors in Herpes Simplex Virus (HSV) and Human Cytomegalovirus (HCMV) Infections and Immunity.Frontiers in immunology · 2019
   Review
6. A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection.NPJ vaccines · 2018
   Review
7. Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging.PLoS pathogens · 2017
   Article
8. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.Journal of virology · 2015
   Article
9. Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Current clinical microbiology reports · 2015
   Article
10. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.Journal of virology · 2015
    Article
11. Anti-glycoprotein g antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.Viruses · 2014
    Article
12. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans.Journal of virology · 2014
    Article
13. Inhibitors of signal peptide peptidase (SPP) affect HSV-1 infectivity in vitro and in vivo.Experimental eye research · 2014
    Article
14. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.PloS one · 2014
    Article

Corrections and comments

• Comment on
  Correlate of immune protection against HSV-1 genital disease in vaccinated women.2014

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as